Theravance Biopharma leans heavily on one key medicine, and growing pressure from governments and insurers on drug prices could make that strength harder to sustain. A late-stage drug readout and new partnerships could broaden its future, but the path depends on clearing tougher approval and reimbursement hurdles.Read more
Theravance leans heavily on one breathing treatment that may be quietly becoming the go-to choice in both hospitals and at home, which could surprise if it keeps taking share. A second drug aimed at a rare condition could open a new, high-profit line of business, but the bet comes with real risk if pricing pressure rises or the pipeline doesn’t deliver.Read more
Key Takeaways Sustained demand for key therapies and new product approvals support revenue growth, expanded margins, and enhanced operating leverage in both established and emerging markets. Streamlined cost structure, controlled spending, and a robust cash position reduce financial risk while enabling reinvestment in pipeline assets and supporting future earnings growth.Read more
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
